"Survival in Children with Perinatally Acquired Human Immunodeficiency" Virus Type 1 Infection

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

"Survival in Children with Perinatally Acquired Human Immunodeficiency" Virus Type 1 Infection

New England Journal of Medicine (12/28/89) Vol. 321, No. 26, P.1791
Scott, Gwendolyn B., et al.

Abstract: Children with perinatally acquired HIV-1 infection have a very poor prognosis, most becoming symptomatic before one year of age, according to researchers Gwendolyn Scott and colleagues of the University of Miami School of Medicine. The researchers report that in a study of 172 children with perinatally-acquired AIDS, the median survival time was 38 months from the time of diagnosis, with mortality highest in the first year of life. Early age at diagnosis and the first identifiable pattern of clinical disease were independently related to survival. The most common first manifestations of disease were lymphoid interstitial pneumonia, encephalopathy, recurrent bacterial infections, and candida esophagitis. The researchers conclude that early diagnosis is critical for prophylactic or antiviral treatment because of the short interval before progressive disease begins.

891228
AD890014

Copyright © 1989 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.